APOE — Apolipoprotein E

APOE — Apolipoprotein E

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">apoe</th>
</tr>
<tr>
<td class="label">Genotype</td>
<td>Relative Risk</td>
</tr>
<tr>
<td class="label">ε3/ε3</td>
<td>1.0 (baseline)</td>
</tr>
<tr>
<td class="label">ε3/ε4</td>
<td>2.5-3.0x</td>
</tr>
<tr>
<td class="label">ε4/ε4</td>
<td>8-12x</td>
</tr>
<tr>
<td class="label">ε2/ε2 or ε2/ε3</td>
<td>0.5-0.6x</td>
</tr>
<tr>
<td class="label">Allele</td>
<td>General Population</td>
</tr>
<tr>
<td class="label">ε3/ε3</td>
<td>~60%</td>
</tr>
<tr>
<td class="label">ε3/ε4</td>
<td>~20-25%</td>
</tr>
<tr>
<td class="label">ε4/ε4</td>
<td>~2-3%</td>
</tr>
<tr>
<td class="label">ε2 carriers</td>
<td>~10-15%</td>
</tr>
<tr>
<td class="label">Consideration</td>
<td>Recommendation</td>
</tr>
<tr>
<td class="label">Drug selection</td>
<td>Consider earlier aggressive intervention</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>May require adjusted dosing for immunotherapies</td>
</tr>
<tr>
<td class="label">Monitoring</td>
<td>More frequent biomarker monitoring</td>
</tr>
<tr>
<td class="label">Lifestyle</td>
<td>Aggressive cardiovascular risk management</td>
</tr>
<tr>
<td class="label">Clinical trials</td>
<td>Prioritize ApoE4-stratified trials</td>
</tr>
<tr>
<td class="label">Consideration</td>
<td>Recommendation</td>
</tr>
<tr>
<td class="label">Standard

APOE — Apolipoprotein E

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">apoe</th>
</tr>
<tr>
<td class="label">Genotype</td>
<td>Relative Risk</td>
</tr>
<tr>
<td class="label">ε3/ε3</td>
<td>1.0 (baseline)</td>
</tr>
<tr>
<td class="label">ε3/ε4</td>
<td>2.5-3.0x</td>
</tr>
<tr>
<td class="label">ε4/ε4</td>
<td>8-12x</td>
</tr>
<tr>
<td class="label">ε2/ε2 or ε2/ε3</td>
<td>0.5-0.6x</td>
</tr>
<tr>
<td class="label">Allele</td>
<td>General Population</td>
</tr>
<tr>
<td class="label">ε3/ε3</td>
<td>~60%</td>
</tr>
<tr>
<td class="label">ε3/ε4</td>
<td>~20-25%</td>
</tr>
<tr>
<td class="label">ε4/ε4</td>
<td>~2-3%</td>
</tr>
<tr>
<td class="label">ε2 carriers</td>
<td>~10-15%</td>
</tr>
<tr>
<td class="label">Consideration</td>
<td>Recommendation</td>
</tr>
<tr>
<td class="label">Drug selection</td>
<td>Consider earlier aggressive intervention</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>May require adjusted dosing for immunotherapies</td>
</tr>
<tr>
<td class="label">Monitoring</td>
<td>More frequent biomarker monitoring</td>
</tr>
<tr>
<td class="label">Lifestyle</td>
<td>Aggressive cardiovascular risk management</td>
</tr>
<tr>
<td class="label">Clinical trials</td>
<td>Prioritize ApoE4-stratified trials</td>
</tr>
<tr>
<td class="label">Consideration</td>
<td>Recommendation</td>
</tr>
<tr>
<td class="label">Standard protocols</td>
<td>Standard dosing appropriate</td>
</tr>
<tr>
<td class="label">Monitoring</td>
<td>Regular monitoring per guidelines</td>
</tr>
<tr>
<td class="label">Lifestyle</td>
<td>General brain health recommendations</td>
</tr>
<tr>
<td class="label">Consideration</td>
<td>Recommendation</td>
</tr>
<tr>
<td class="label">Risk profile</td>
<td>May have protective effect</td>
</tr>
<tr>
<td class="label">Treatment</td>
<td>Standard protocols, monitor for undertreatment</td>
</tr>
<tr>
<td class="label">Prognosis</td>
<td>Generally more favorable prognosis</td>
</tr>
<tr>
<td class="label">Genotype</td>
<td>AD Risk</td>
</tr>
<tr>
<td class="label">ε3/ε3</td>
<td>Baseline (1x)</td>
</tr>
<tr>
<td class="label">ε3/ε4</td>
<td>~3x increased</td>
</tr>
<tr>
<td class="label">ε4/ε4</td>
<td>~12x increased</td>
</tr>
<tr>
<td class="label">ε2/ε3</td>
<td>~0.6x (protective)</td>
</tr>
<tr>
<td class="label">Process</td>
<td>Role</td>
</tr>
<tr>
<td class="label">Astrocyte production</td>
<td>Secretes ApoE-lipoprotein particles</td>
</tr>
<tr>
<td class="label">Neuronal uptake</td>
<td>Via LDLR and LRP1 receptors</td>
</tr>
<tr>
<td class="label">Synapse maintenance</td>
<td>Delivers lipids for synaptic membranes</td>
</tr>
<tr>
<td class="label">Myelin support</td>
<td>Provides lipids for oligodendrocytes</td>
</tr>
<tr>
<td class="label">Isoform</td>
<td>Lipid Efflux</td>
</tr>
<tr>
<td class="label">APOE2</td>
<td>Normal</td>
</tr>
<tr>
<td class="label">APOE3</td>
<td>Normal</td>
</tr>
<tr>
<td class="label">APOE4</td>
<td>Reduced</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Gene editing</td>
<td>APOE4 → APOE3 conversion</td>
</tr>
<tr>
<td class="label">Small molecules</td>
<td>APOE4 structure correctors</td>
</tr>
<tr>
<td class="label">ApoE mimetics</td>
<td>LRP1 activation</td>
</tr>
<tr>
<td class="label">Lipid modulation</td>
<td>Restore lipid homeostasis</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Cortex (astrocytes)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>High</td>
</tr>
<tr>
<td class="label">White matter</td>
<td>Medium</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's" style="color:#ef9a9a">ALZHEIMER'S</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-c9c79e3e" style="color:#ce93d8" title="Score: 0.59">APOE4-Selective Lipid Nanoemulsion Thera...</a><br><a href="/hypothesis/h-seaad-fa5ea82d" style="color:#ce93d8" title="Score: 0.57">APOE Isoform Expression Across Glial Sub...</a><br><a href="/hypothesis/h-15336069" style="color:#ce93d8" title="Score: 0.53">APOE Isoform Conversion Therapy...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">2342 edges</a></td>
</tr>
</table>

Pathway Diagram

'
kim2026:
authors: Kim D et al
title: Apolipoprotein E Deficiency Impairs Human Microglial Proliferation Accompanied by Elevated Cellular Oxidative Stress
journal: Cell Mol Neurobiol
year: 2026
pmid: '41860014'
barger2026:
authors: Barger SW et al
title: 'Modulation of apolipoprotein E receptor-2 by ApoE4, amyloid beta-peptide, reelin, and secreted amyloid precursor protein: a common point of impact in Alzheimer''s disease pathogenesis'
journal: J Biol Chem
year: 2026
pmid: '41858499'
norgren2026:
authors: Norgren J et al
title: Meat Consumption and Cognitive Health by APOE Genotype
journal: J Gerontol A Biol Sci Med Sci
year: 2026
pmid: '41854609'

Introduction

Apoe — [Apolipoprotein E](/proteins/apoe-protein) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [@apoe2021]

Overview

APOE ([Apolipoprotein E](/proteins/apoe)) is a gene located on chromosome 19q13.32 that plays a critical role in neurodegenerative disease. Mutations in APOE are associated with [Alzheimer's Disease/diseases), Cardiovascular Disease. The gene is catalogued as NCBI Gene ID [348](https://www.ncbi.nlm.nih.gov/gene/348) and OMIM [107741](https://omim.org/entry/107741). [@apoe2024]

The protein encoded by APOE is [ApoE/proteins). See the protein page for detailed structural and functional information. [@lithium2024]

APOE is one of the most significant genetic risk factors for late-onset Alzheimer's disease (LOAD). The APOE ε4 allele increases disease risk in a dose-dependent manner, while the APOE ε2 allele appears to be protective. [@tau2025]

--- [@apoe]

Function

The APOE gene encodes a protein that is expressed in multiple brain regions including [Astrocytes](/cell-types/astrocytes), Liver, Cerebral [cortex](/brain-regions/cortex), [Hippocampus](/brain-regions/hippocampus). The normal function of this gene product is essential for neuronal health and survival. [^6]

Brain Expression

• [Astrocytes](/cell-types/astrocytes) Liver
• Cerebral cortex
• Hippocampus

Normal Physiological Functions

Lipid Transport and Metabolism

ApoE is a major lipoprotein particle that plays a critical role in lipid transport throughout the body and in the central nervous system:

• Cholesterol transport: ApoE facilitates the delivery of cholesterol and phospholipids to [neurons](/entities/neurons) via ApoE receptor-mediated endocytosis
• Lipid homeostasis: Regulates plasma lipid levels and maintains cellular lipid composition
• CNS lipid metabolism: Astrocytes produce and secrete ApoE-containing lipoproteins that are essential for neuronal lipid supply

Neuronal Support Functions

• Synaptic plasticity: ApoE modulates synaptic formation and remodeling, critical for learning and memory
• Axonal myelination: Supports proper myelination of neurons by oligodendrocytes
• Neuroprotection: Exhibits antioxidant and anti-inflammatory properties under normal conditions

Mechanistic Role in Alzheimer's Disease

Amyloid-Beta Metabolism

ApoE plays a complex role in [Aβ](/proteins/amyloid-beta-protein) metabolism through multiple pathways:

Tau Pathology and Neurofibrillary Degeneration

• ApoE4 exacerbates [tau](/proteins/tau)-mediated neurodegeneration through impaired [autophagy](/entities/autophagy) and lysosomal function
• [Tau](/proteins/tau) pathology progression correlates with ApoE4 carrier status in AD patients
• ApoE4 enhances [tau](/proteins/tau)-induced synaptic loss and mitochondrial dysfunction

Neuroinflammation

• Microglial activation: ApoE4 promotes a pro-inflammatory microglial phenotype
• Cytokine production: Increases production of IL-1β, TNF-α, and other neurotoxic cytokines
• Complement activation: Enhances complement-mediated synaptic elimination

Vascular Contributions

• Cerebral amyloid angiopathy (CAA): ApoE4 accelerates Aβ deposition in cerebral blood vessels
• Blood-brain barrier dysfunction: Impairs endothelial tight junction integrity
• Hypoxia response: Exacerbates cerebrovascular pathology in AD

Disease Associations

APOE mutations are linked to the following neurodegenerative conditions:

• [Alzheimer's Disease/diseases) — strongest genetic risk factor for late-onset AD
• Cardiovascular Disease — hypercholesterolemia and atherosclerosis

Key Mutations

• APOE ε4 (C112R + R158C risk allele) — increases AD risk 3-4 fold (heterozygous) to 8-12 fold (homozygous)
• APOE ε2 (C112C + C158C protective) — may provide protection against AD
• Christchurch (R136S protective) — rare protective mutation that may reduce AD risk even in ε4 carriers

Alzheimer's Disease Risk by Genotype

Therapeutic Implications

Current Approaches

• ApoE-directed therapies: Small molecules that can modulate ApoE expression or function
• Gene therapy: AAV-mediated delivery of protective APOE alleles
• [LRP1](/proteins/lrp1) modulators: Enhancing Aβ clearance through lipoprotein receptor pathways

Research Directions

• ApoE mimetic peptides for neuroprotection
• Anti-ApoE4 antibodies to neutralize toxic effects
• Lifestyle interventions particularly beneficial for ε4 carriers (exercise, cognitive training)

CBS/PSP Therapeutic Implications

APOE genotype has emerging implications for corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP) treatment strategies.

APOE Allele Frequencies in CBS/PSP

Impact on Disease Risk and Progression

• APOE ε4 carriers with CBS/PSP may experience more rapid disease progression
• APOE ε4/ε4 homozygotes show increased risk for earlier onset and more severe tau pathology
• APOE ε2 carriers may have slower disease progression, though evidence is less robust than in AD
• Tau burden in CBS/PSP correlates with APOE4 status, similar to patterns observed in AD

Response to Tau-Targeted Therapies

Tau Immunotherapy

• ApoE4 carriers show altered response to anti-tau monoclonal antibodies
• Reduced efficacy observed in ε4/ε4 patients compared to non-carriers
• May require higher dosing or combination approaches for ApoE4 carriers
• Blood-brain barrier penetration may be compromised in APOE4 carriers

Lithium Treatment

• Lithium response may vary by APOE genotype in CBS/PSP
• ε4 carriers show reduced neuroprotective response to lithium in some studies
• Combination strategies (lithium + other agents) may be needed for APOE4 carriers
• ApoE status should inform lithium dosing considerations

Personalized Treatment Recommendations

For APOE4 Carriers (ε3/ε4 or ε4/ε4)

For Non-Carriers (ε3/ε3)

For ε2 Carriers

Clinical Trial Considerations

• APOE genotype should be considered for patient stratification in tau-directed therapy trials
• ε4 carriers may benefit from enriched enrollment in clinical trials
• Pharmacodynamic responses differ by genotype, requiring genotype-aware endpoints

Emerging Research

• APOE-Tau interaction: Growing evidence for APOE-mediated modulation of tau propagation
• Neuroinflammation: APOE4 enhances microglial activation in CBS/PSP
• Combination therapies: ApoE-targeted approaches being developed for tauopathies
• Biomarker development: APOE-stratified biomarker validation ongoing

Key Publications

[@barger2026]: Barger SW et al. Modulation of apolipoprotein E receptor-2 by ApoE4, amyloid β-peptide, reelin, and secreted amyloid precursor protein: a common point of impact in Alzheimer's disease pathogenesis. J Biol Chem. 2026. PMID: 41858499(https://pubmed.ncbi.nlm.nih.gov/41858499/)

[@norgren2026]: Norgren J et al. Meat Consumption and Cognitive Health by APOE Genotype. J Gerontol A Biol Sci Med Sci. 2026. PMID: 41854609(https://pubmed.ncbi.nlm.nih.gov/41854609/)

External Links

• NCBI Gene: [https://www.ncbi.nlm.nih.gov/gene/348](https://www.ncbi.nlm.nih.gov/gene/348)
• Ensembl: [https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000130203](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000130203)
• OMIM: [https://omim.org/entry/107741](https://omim.org/entry/107741)
• UniProt: [https://www.uniprot.org/uniprot/P02649](https://www.uniprot.org/uniprot/P02649)
• Allen Human Brain Atlas: [APOE expression](https://human.brain-map.org/microarray/search/show?search_term=APOE)
• [Genes Index](/genes)
• [Proteins Index](/proteins)
• [ApoE Protein](/proteins/apoe-protein)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• APOE Lipid Metabolism Pathway
• [Mechanisms Index](/mechanisms)
• --

Background

The study of Apoe — Apolipoprotein E has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Brain Atlas Resources

Expression data from the Allen Brain Atlas provides valuable insights into APOE expression patterns:

• [Allen Human Brain Atlas - APOE Expression](https://human.brain-map.org/microarray/search/show?search_term=APOE): Gene expression data across brain regions
• [Allen Mouse Brain Atlas - Apoe Expression](https://mouse.brain-map.org/gene/show?gene_id=11892): Mouse model expression data
• [BrainSpan Atlas - APOE Developmental Expression](https://brainspan.org/static/download.html): Developmental expression patterns

• APOE is expressed at high levels in astrocytes throughout the brain
• Expression is particularly prominent in the hippocampus and cortex
• APOE4 isoform associated with increased amyloid deposition and reduced synaptic plasticity

Recent Research (2025-2026)

Recent APOE research continues to elucidate its role in lipid metabolism and neurodegeneration.

• 2026: [Plasmalogen deficiency and the Alzheimer's disease risk of apolipoprotein E4](https://pubmed.ncbi.nlm.nih.gov/41768790/) reveals mechanisms linking APOE4 to AD risk.
• 2026: [APOE4 and cerebral amyloid angiopathy](https://pubmed.ncbi.nlm.nih.gov/41650002/) reviews vascular contributions to AD.
• 2025: [APOE isoform-specific tau pathology](https://pubmed.ncbi.nlm.nih.gov/41350005/) demonstrates differential effects on neurodegeneration.

APOE4 Risk Allele — Mechanisms

The APOE ε4 allele is the most significant genetic risk factor for late-onset Alzheimer's disease, increasing risk in a dose-dependent manner [1].

Risk by Genotype

Mechanisms of APOE4-Mediated Risk

1. Amyloid-beta Metabolism

APOE4 affects Aβ throughout its lifecycle:

• Clearance impairment: Reduced Aβ clearance via decreased LDLR/LRP1 binding [2]
• Aggregation enhancement: Promotes Aβ oligomerization and plaque formation
• Vascular dysfunction: Impairs Aβ clearance across the blood-brain barrier [3]

2. Tau Pathology Interaction

APOE4 influences tau pathogenesis through:

• Accelerated tau phosphorylation: Enhanced kinase activation
• Tau spread: Facilitates transneuronal tau propagation
• NFT formation: Increased neurofibrillary tangle burden [4]

3. Neuroinflammation

APOE4 promotes inflammatory responses:

• Microglial activation: Enhanced pro-inflammatory cytokine release
• Complement activation: Increased C1q and C3 deposition
• Astrocyte dysfunction: Impaired lipid homeostasis [5]

4. Synaptic Dysfunction

• Synapse loss: Accelerated synaptic elimination
• Plasticity impairment: Reduced spine density
• Network dysfunction: Impaired hippocampal plasticity [6]

Lipid Metabolism Role in Neurodegeneration

CNS Cholesterol and APOE

ApoE is the primary transporter of cholesterol in the brain [7]:

APOE Isoform Effects on Lipid Metabolism

Therapeutic Targeting

Approaches in Development

APOE-Genotype Guided Prevention

• Lifestyle intervention: More aggressive in ε4 carriers
• Monitoring: Earlier biomarker screening
• Preventive trials: Enriched for APOE4 carriers [8]

Clinical Significance

APOE Testing

• Risk assessment: Not routinely recommended for prediction
• Research use: Clinical trial enrichment
• Direct-to-consumer: Available but controversial

Future Directions

• APOE4-clearing antibodies: In development
• Gene therapy: AAV-APOE3 expression
• Combination approaches: Multi-target interventions

Key Publications

Structure

AlphaFold DB provides a full-length predicted structure for APOE (UniProt [P02649](https://www.uniprot.org/uniprotkb/P02649/entry), model v6) with mean pLDDT 75.5. View the model at [AlphaFold DB](https://alphafold.ebi.ac.uk/entry/P02649) or download the [PDB file](https://alphafold.ebi.ac.uk/files/AF-P02649-F1-model_v6.pdb).

Domain and region confidence from per-residue pLDDT:

• Residues 80-255 (8 X 22 AA approximate tandem repeats): mean pLDDT 81.7 (confident).
• Residues 80-101 (1): mean pLDDT 89.1 (confident).
• Residues 102-123 (2): mean pLDDT 87.0 (confident).
• Residues 124-145 (3): mean pLDDT 92.3 (very high).
• Residues 158-168 (LDL and other lipoprotein receptors binding): mean pLDDT 94.5 (very high).
• Residues 210-290 (Lipid-binding and lipoprotein association): mean pLDDT 73.1 (confident).
• Residues 266-317 (Homooligomerization): mean pLDDT 70.8 (confident).
• Residues 278-290 (Specificity for association with VLDL): mean pLDDT 79.5 (confident).

UniProt function annotation: APOE is an apolipoprotein, a protein associating with lipid particles, that mainly functions in lipoprotein-mediated lipid transport between organs via the plasma and interstitial fluids (PubMed:14754908, PubMed:1911868, PubMed:6860692). APOE is a core component of plasma lipoproteins and is involved in their production, conversion and clearance.
Subcellular localization: Secreted, Secreted, extracellular space, Secreted, extracellular space, extracellular matrix, Extracellular vesicle, Endosome, multivesicular body.
Curated disease associations include: Hyperlipoproteinemia 3; Alzheimer disease 2; Sea-blue histiocyte disease.

References

References (1)

[@apoe]: [ApoE4 ex---

*Page aut## Allen Brain Atlas Data

Gene Expression

• Astrocytes - Primary production site in the brain
• Microglia - Expression in immune cells
• Cerebral cortex - Astrocytic expression
• Hippocampus - Astrocytic processes

Single-Cell Expression

• Astrocytes (GFAP+)
• Microglia (TMEM119+)
• Some oligodendrocytes
• Hepatocytes (outside brain)

Brain Region Expression

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Competitive APOE4 Domain Stabilization Peptides](/hypothesis/h-d0a564e8) — <span style="color:#ffd54f;font-weight:600">0.51</span> · Target: APOE
• [Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)](/hypothesis/h-11795af0) — <span style="color:#ffd54f;font-weight:600">0.51</span> · Target: APOE
• [Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides](/hypothesis/h-b948c32c) — <span style="color:#ffd54f;font-weight:600">0.49</span> · Target: APOE, LRP1, LDLR
• [APOE4 Allosteric Rescue via Small Molecule Chaperones](/hypothesis/h-44195347) — <span style="color:#ffd54f;font-weight:600">0.46</span> · Target: APOE
• [Targeted APOE4-to-APOE3 Base Editing Therapy](/hypothesis/h-a20e0cbb) — <span style="color:#ffd54f;font-weight:600">0.43</span> · Target: APOE
• [Interfacial Lipid Mimetics to Disrupt Domain Interaction](/hypothesis/h-99b4e2d2) — <span style="color:#ff8a65;font-weight:600">0.37</span> · Target: AP## Pathway Diagram (2)gram

<!-- scidex-demo:links:start -->

SciDEX Links

Related Hypotheses

• [Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)](/hypothesis/h-11795af0) — score 0.79; target APOE; neurodegeneration.
• [Competitive APOE4 Domain Stabilization Peptides](/hypothesis/h-d0a564e8) — score 0.78; target APOE; neurodegeneration.
• [APOE4 Allosteric Rescue via Small Molecule Chaperones](/hypothesis/h-44195347) — score 0.76; target APOE; neurodegeneration.
• [Targeted APOE4-to-APOE3 Base Editing Therapy](/hypothesis/h-a20e0cbb) — score 0.76; target APOE; neurodegeneration.

Related Analyses

• [Lipid metabolism dysregulation and membrane integrity in Alzheimer disease](/analyses/SDA-2026-04-04-frontier-lipidomics-dcdbc360)
• [TREM2 agonism vs antagonism in DAM microglia](/analyses/SDA-2026-04-01-gap-001)
• [APOE4 structural biology and therapeutic targeting strategies](/analyses/SDA-2026-04-01-gap-010)

Associated Diseases

• Als — associated with

• ALS — associated with

• Alzheimer — associated with

• alzheimer_disease — associated with

• Alzheimer disease — associated with

• Alzheimer Disease — associated with

• Alzheimer's disease — associated with

• Alzheimer's Disease — associated with

• Alzheimer'S Disease — associated with

• amyotrophic lateral sclerosis — associated with

• Amyotrophic Lateral Sclerosis — associated with

• dementia — associated with

• Dementia — associated with

• frontotemporal dementia — associated with

• Frontotemporal Dementia — causes

• FRONTOTEMPORAL DEMENTIA — associated with

• Late-onset Alzheimer's disease — risk factor for

• Late-Onset Alzheimer's Disease — risk factor for

• Late-Onset Alzheimer'S Disease — risk factor for

• Lewy body dementia — associated with

• Other Dementias — risk factor for

• Parkinson — associated with

• Parkinson's disease — associated with

• Parkinson's Disease — associated with

• PARKINSON'S DISEASE — associated with

• Parkinson's disease dementia — implicated in

GWAS Evidence

Genetic associations from the [NHGRI-EBI GWAS Catalog](https://www.ebi.ac.uk/gwas/) supporting gene-disease relationships:

• rs9497975 — (p = 7.00e-08, n = ) [ ](https://www.ebi.ac.uk/gwas/studies/)
• rs3815087 — HIV-1 control (p = 8.00e-08, n = 2,362 European ancestry cases) [PLoS Genet PMID:20041166](https://pubmed.ncbi.nlm.nih.gov/20041166/)
• rs212388 — Crohn's disease (p = 3.00e-14, n = Up to 12,924 European ancestry cases, up to 21,442 European ancestry controls ) [Nature PMID:23128233](https://pubmed.ncbi.nlm.nih.gov/23128233/)
• rs4654925 — Ulcerative colitis (p = 9e-22, n = 1,043 European ancestry cases, 1,703 European ancestry controls) [Nat Genet PMID:20228798](https://pubmed.ncbi.nlm.nih.gov/20228798/)
• rs2138852 — Mean platelet volume (p = 7e-28, n = 1,606 European ancestry individuals) [Am J Hum Genet PMID:19110211](https://pubmed.ncbi.nlm.nih.gov/19110211/)
• rs12049330 — Major depressive disorder (p = 6.00e-06, n = 1,020 European ancestry cases, 1,636 European ancestry controls) [Mol Psychiatry PMID:20125088](https://pubmed.ncbi.nlm.nih.gov/20125088/)
• rs1128334 — Systemic lupus erythematosus (p = 2.00e-11, n = 314 Chinese ancestry cases, 1,484 Chinese ancestry controls) [PLoS Genet PMID:20169177](https://pubmed.ncbi.nlm.nih.gov/20169177/)

Molecular Interaction Map: APOE4 Pathway

Detailed interaction network covering cholesterol trafficking, Abeta clearance, and synaptic vulnerability downstream of the APOE4 risk allele. Key nodes: ABCA1 (lipidation), LRP1/LDLR (receptor uptake), APP/Abeta (amyloid generation), SORL1 (endocytic sorting), CLU (alternative chaperone), RELN (synaptic signaling), and TREM2 (microglial sensor).